MedTrace Logo

Evaluation of the Treatment With Klacid®SR in Patients With Lower Respiratory Tract Infection

NCT01108185 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3181

Last updated 2011-09-13

Study results available
· View outcomes & findings →

Summary

The aim of this post-marketing observational study (PMOS) is to describe the relief of symptoms, tolerability and compliance of treatment with Klacid®SR in a dose 1000 mg once daily in patients with lower respiratory tract infection or in patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP).

Conditions

  • Tracheitis
  • Tracheobronchitis
  • Bronchitis
  • Chronic Bronchitis
  • Community-acquired Pneumonia

Sponsors & Collaborators

Principal Investigators

  • Adam Hloska, M.D. · Abbott

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Slovakia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01108185 on ClinicalTrials.gov